Timothy J. Barberich Purchases 30,000 Shares of Verastem Inc (VSTM) Stock

Verastem Inc (NASDAQ:VSTM) Director Timothy J. Barberich purchased 30,000 shares of the stock in a transaction dated Monday, May 15th. The shares were acquired at an average price of $2.45 per share, with a total value of $73,500.00. Following the completion of the acquisition, the director now owns 69,462 shares in the company, valued at approximately $170,181.90. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Verastem Inc (NASDAQ:VSTM) traded up 3.07% during trading on Friday, reaching $2.35. The company had a trading volume of 187,857 shares. Verastem Inc has a 52 week low of $1.05 and a 52 week high of $2.54. The firm’s market capitalization is $86.93 million. The firm has a 50-day moving average of $2.03 and a 200 day moving average of $1.45.

Verastem (NASDAQ:VSTM) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). On average, equities research analysts forecast that Verastem Inc will post ($1.31) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was posted by Mideast Time and is the sole property of of Mideast Time. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.mideasttime.com/timothy-j-barberich-purchases-30000-shares-of-verastem-inc-vstm-stock/1707902.html.

A number of equities analysts have recently weighed in on the company. Oppenheimer Holdings Inc. set a $6.00 price target on Verastem and gave the stock a “buy” rating in a report on Wednesday, May 10th. Cann reiterated a “buy” rating and set a $2.00 price target on shares of Verastem in a report on Thursday, May 11th. Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 price target on shares of Verastem in a report on Thursday, May 11th. Zacks Investment Research cut Verastem from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, CIBC reiterated an “outperform” rating and set a $6.00 price target on shares of Verastem in a report on Thursday, April 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $3.64.

A number of large investors have recently made changes to their positions in VSTM. Renaissance Technologies LLC raised its stake in shares of Verastem by 20.0% in the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after buying an additional 204,400 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Verastem by 0.4% in the first quarter. Geode Capital Management LLC now owns 188,743 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 750 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Verastem by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,036,613 shares of the biopharmaceutical company’s stock valued at $2,145,000 after buying an additional 51,306 shares in the last quarter. TFS Capital LLC purchased a new stake in shares of Verastem during the first quarter valued at approximately $113,000. Finally, FMR LLC raised its stake in shares of Verastem by 32.2% in the fourth quarter. FMR LLC now owns 901,200 shares of the biopharmaceutical company’s stock valued at $1,009,000 after buying an additional 219,445 shares in the last quarter.

Verastem Company Profile

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

5 Day Chart for NASDAQ:VSTM

Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.